There has been longstanding interest in the relationship between the immune system and malignant melanoma, the deadliest form of skin cancer. Melanoma has been the tumor of choice for the evaluation of a wide variety of therapeutic approaches that rely on stimulation of the immune system to combat cancer. Early clinical trials of modulators of immune checkpoints, including agents that block CTLA-4 and PD-1 signaling, focused on melanoma for the evaluation of clinical responses. The striking responses to immune checkpoint inhibitors noted in some melanoma patients have now been observed in several other malignancies, including renal cell, lung, breast, bladder, and prostate cancer. These findings are very encouraging, however the specific mechanisms of response and reasons why only a subset of patients respond to therapy are not known. Based on the critical role that mouse models played in the identification of CTLA-4 and PD-1 as immune checkpoints and therapeutic targets in cancer, it is likely that human-relevant animal models will be required to understand mechanisms of response and to optimize therapy so that a larger proportion of patients respond. We have generated a series of genetically engineered mouse models that reflect the genetic diversity of human melanoma and isolated corresponding congenic melanoma cells lines that form tumors following injection into immune competent C57Bl/6J mice. The genetic models and series of congenic lines represents an ideal set of models for the study of cancer immunology and response to immune therapies. We propose to characterize and validate these melanoma models, evaluate the effects of tumor genotype and mutational burden, and compare immune responses with those seen in human melanoma. Furthermore, we propose to characterize immune responses in novel melanoma brain metastasis and systemic metastasis models. We will make all of the findings and approaches available through the Oncology Models Forum.

Public Health Relevance

The proposed experiments will characterize and validate a new system of genetically engineered and congenic melanoma models that allow for evaluation of immune responses to tumor formation and immune therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA196660-03
Application #
9445404
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Mccarthy, Susan A
Project Start
2016-04-01
Project End
2019-03-31
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
3
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Yale University
Department
Dermatology
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Wang, Jake; Perry, Curtis J; Meeth, Katrina et al. (2017) UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model. Pigment Cell Melanoma Res 30:428-435
Damsky, W E; Bosenberg, M (2017) Melanocytic nevi and melanoma: unraveling a complex relationship. Oncogene 36:5771-5792
Ho, Ping-Chih; Kaech, Susan M (2017) Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries. Curr Opin Immunol 46:38-44
Meeth, Katrina; Wang, Jake Xiao; Micevic, Goran et al. (2016) The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations. Pigment Cell Melanoma Res 29:590-7